Anita Joshi

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 337 citations · Full text

Medicine, Hematology, Oncology +11

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Primary Endpoint Results of the EVOLVE Trial

Ian T. Meredith, Stefan Verheye, Christophe Dubois et al. · Journal of the American College of Cardiology · 2012 · 203 citations

Medicine, Biostatistics, Outcomes Research +4

TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions

Eberhard Grube, Keith D. Dawkins, Giulio Guagliumi et al. · EuroIntervention · 2009 · 62 citations

Medicine, Cardiology, Surgery +17

IFN-γ Release Assay Conversions and Reversions. Challenges with Serial Testing in U.S. Health Care Workers

Manish Joshi, Thomas P. Monson, Anita Joshi et al. · Annals of the American Thoracic Society · 2014 · 56 citations

Public Health, Infectious Disease Control, Infectious Diseases +17